A Medical Device Daily

Staar Surgical (Monrovia, California), a maker of implantable lenses and other ophthalmic products, reported the pricing of an underwritten public offering of 3.1 million shares of its common stock at $5 a share for gross proceeds of about $15.65 million.

All shares of the common stock offered by Staar are being sold according to a shelf registration statement that was declared effective by the Securities and Exchange Commission on Aug. 8, 2006. The underwriter has agreed to buy the shares from Staar, subject to customary closing conditions. Staar also granted the underwriter in the offering an option to buy up to an additional 469,565 shares to cover over-allotments, if any. The offering is expected to close May 1.

Pacific Growth Equities acted as the sole underwriter for this offering.

Lifeline Biotechnologies (Reno, Nevada) has extended the date for its common shareholders to submit their common stock certificates according to its exchange program.

Lifeline is offering to exchange its Series B convertible preferred stock, which the company is valuing at $1 a share, for common shares of stock submitted to its transfer agent by May 18, which the company is valuing at $.001 a share, a premium to the current market price.

This means for every 1,600 shares of common stock submitted to Lifeline for exchange, shareholders will receive one share of Series B convertible preferred stock valued at $1 for future conversion purposes.

Current shareholders must have their shares to OTC Corporate Transfer Service Company by May 18, unless extended, in order to qualify for the exchange of common shares to Series B convertible preferred shares. Shareholders must submit a minimum of 100,000 shares of common stock. The Series B convertible preferred stock will be protected from any future stock restructuring by Lifeline.

Lifeline develops technologies designed to assist in the early detection of cancers. It says that its First Warning System, a process for assisting in the early detection of breast cancer, is in development.